Amlodipine Nicotinate

The present study quantified simultaneous determination of the active components included in Valzomix HCT tablets are hydrochlorothiazide (HCT), valsartan (VAL), and amlodipine (AML). Two chemometric methods-continuous wavelet transform (CWT) and ratio subtraction (RS)-along with a rapid and effective spectrophotometric approach-which does not require preparatory separation-were used to do the analysis. The CWT approach applied the zero-crossing method to analyze several wavelet families and selected the Daubechies 2, Symlet 2, and Biorthogonal 1.3 wavelets. At wavelengths of 215, 224, and 233 nm, respectively, each wavelet was selected based on its unique scale characteristics for the purpose of measuring the medicines. The quantification and detection limits for AML and VAL varied between 0.0406 and 0.3906 μg/mL, with recovery rates sometimes above 97 % and root mean square errors below 2. The RS technique identified satisfactory values between 0.1594 and 0.1663 μg/mL. The recovery rates varied from 99.52 % to 102.70 %, with quantification limits of 0.3064 to 0.7669 μg/mL. Both approaches demonstrated relative standard deviations below 1 % and average recovery rates over 94 % in the sample analysis. A one-way ANOVA with a 95 % confidence interval demonstrated no major variances in the methods.

The incorporation of nanotechnol. in medicine has led to the development of advanced imaging agents, particularly at the nanoscale.Magnetic Resonance Imaging (MRI) stands out in medical imaging due to its non-invasive nature and superior soft tissue contrast.However, the low sensitivity of current MRI contrast agents necessitates the development of improved alternatives.Gadolinium-based contrast agents (GBCAs) enhance diagnostic capabilities but pose toxicity risks, particularly in patients with severe chronic kidney diseases.This study aims to design and synthesize a novel gadolinium-loaded, citric acid-based polyethylene glycol (PEG) dendrimer (dendrimer-G₂) conjugated with amlodipine for enhanced cardiac MR imaging.The final product was characterized using LC-Mass, TEM, and EDX.Cytotoxicity was assessed using the MTT assay on HEK-293 cells.The MR imaging potential and biodistribution were evaluated in vivo, with mice receiving injections of the Gd³⁺-dendrimer-amlodipine complex followed by MRI and plasma mass spectrometry anal.Our result showed that the Gd³⁺-dendrimer-amlodipine complex demonstrated no cytotoxic effects across all tested concentrationsThe complex exhibited superior in vitro relaxivity (r₁) compared to Magnevist, indicating enhanced contrast properties.In vivo studies showed significant cardiac uptake and efficient excretion through renal and hepatobiliary systems, confirming its potential for targeted cardiac imaging.In conclusion, the synthesized Gd³⁺-dendrimer-amlodipine complex demonstrates promising biocompatibility, favorable contrast properties, and efficient excretion patterns in preliminary studies.Further in vivo investigations are warranted to confirm its efficacy and safety profile as a novel MR contrast agent.